Go Pro
→ Your book is inside (From Profits Run) (Ad)tc pixel
NASDAQ:IVVD

Invivyd Q2 2026 Earnings Report

Invivyd logo
$0.57 +0.03 (+4.79%)
As of 02:00 PM Eastern
This is a fair market value price provided by Massive. Learn more.
ProfileEarnings HistoryForecast

Invivyd EPS Results

Actual EPS
N/A
Consensus EPS
-$0.15
Beat/Miss
N/A
One Year Ago EPS
N/A

Invivyd Revenue Results

Actual Revenue
N/A
Expected Revenue
$14.40 million
Beat/Miss
N/A
YoY Revenue Growth
N/A

Invivyd Announcement Details

Quarter
Q2 2026
Date
8/13/2026
Time
Before Market Opens
Conference Call Date
Wednesday, August 12, 2026
Conference Call Time
9:30AM ET

Conference Call Resources

Invivyd Earnings Headlines

Invivyd Receives Nasdaq Notice for Bid Price Deficiency
July 24, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/invivyd-receives-nasdaq-notice-for-bid-price-deficiency?utm_source=marketbeat.com&utm_medium=referral
Invivyd Announces Receipt of Twelve Months’ Advanced Notice of Emergency Use Authorization (EUA) Termination for PEMGARDA® and Provides an Update on Next Steps with the U.S. FDA
July 6, 2026  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/invivyd-announces-receipt-of-twelve-months-advanced-notice-of-emergency-use-authorization-eua-termination-for-pemgarda-and-provides-an-update-on-next-steps-with-the-u-s-fda-1036299245
A letter from Shannon Stansberry
Porter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down year in nearly two decades and total gains of almost 2,000% - his immediate reaction was disbelief. It took a trusted friend's personal vouching for Emmet Savage and a face-to-face trip to Ireland to change his mind. The full documentary, Investigating Project Prophet, is now live.tc pixel
July 30 at 1:00 AM  |  Porter & Company (Ad)
IVVD Stock Drops As PEMGARDA Loses Emergency Authorization In 2027 — Invivyd Eyes Full FDA Approval
July 6, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/markets/stocks/articles/ivvd-stock-drops-pemgarda-loses-173927823.html
Invivyd, Inc. Announces FDA Notice of Termination for PEMGARDA EUA Following HHS COVID-19 Emergency Declaration Wind-Down
July 6, 2026  |  quiverquant.comQ
Invivyd Announces Receipt of Twelve Months' Advanced Notice of Emergency Use Authorization (EUA) Termination for PEMGARDA® and Provides an Update on Next Steps with the U.S. FDA
July 6, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/07/06/3322321/0/en/invivyd-announces-receipt-of-twelve-months-advanced-notice-of-emergency-use-authorization-eua-termination-for-pemgarda-and-provides-an-update-on-next-steps-with-the-u-s-fda.html
See More Invivyd Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Invivyd? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Invivyd and other key companies, straight to your email.

About Invivyd

Invivyd (NASDAQ:IVVD), a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering. Its pipeline includes PEMGRADA (pemivibart) injection, a half-life extended investigational monoclonal antibody (mAb) for the prevention of COVID-19 in adults and adolescents; VYD2311, an mAb candidate which is in preclinical studies for the prevention or treatment for COVID-19; and adintrvimab, that is in phase 3 clinical trials for the prevention or treatment of COVID-19. The company also has discovery stage candidates for the prevention of seasonal influenza and COVID-19. It has a collaboration agreement with Adimab, LLC for the discovery and optimization of proprietary antibodies; and the Scripps Research Institute to perform research activities to identify vaccine candidates for the prevention, diagnosis or treatment of influenza or beta coronaviruses. The company was formerly known as Adagio Therapeutics, Inc. and changed its name to Invivyd, Inc. in September 2022. Invivyd, Inc. was incorporated in 2020 and is headquartered in Waltham, Massachusetts.

View Invivyd Profile
Earnings Tools